CCC
ABMD

Chelsea Counsel Company’s Abiomed Inc ABMD Stock Holding History

Chelsea Counsel Company’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-490
Closed -$220K – 76
2018
Q3 		$220K Buy
+490
New +$193K 0.11% 73

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Chelsea Counsel Company's ABMD Position: Q4 2018 in Review

Chelsea Counsel Company sold out of Abiomed Inc (ABMD) in Q4 2018, closing a stake of 490 shares — an estimated $220K sold.

Chelsea Counsel Company first reported a position in ABMD in Q3 2018 and held it in 1 quarter. The position peaked at $220K in Q3 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q4 2018.

  • Chelsea Counsel Company reported no remaining Abiomed Inc position as of Q4 2018 after selling out during the quarter.
  • Chelsea Counsel Company sold 490 Abiomed Inc shares in Q4 2018, an estimated $220K.
  • Chelsea Counsel Company first reported a position in Abiomed Inc in Q3 2018 and held it in 1 quarter.
  • Chelsea Counsel Company's Abiomed Inc position peaked at $220K in Q3 2018.
  • 529 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2018.

Based on Chelsea Counsel Company's 13F filing for Q4 2018, filed 9 Dec 2019.